I am planning on performing an illumina multiplex sequencing run on a library of sequences that I have compiled. They are digested out of plasmid and consist of ~10 unvaried nucleotides, 60 varied nucleotides, ~40 unvaried nucleotides, 60 varied nucleotides, then 10 unvaried nucleotides in that order. I have seen in previous papers that there are some issues with the cluster identification step for sequences which are unvaried in their first few nucleotides. Is this still a major problem? Is there a way to get around this without adding extra varied nucleotides to the ends of my sequences? Or is this the only robust solution?
-
-
You need to design a custom sequencing primer.
Use the sequence of the adapter+sequence of your non-variable region(10 bases)
Then create a sequencing primer that is complementary to the last base of your nonvariable region-then work back.
When the Tm of the primer is above 65 (that way it will work on both HiSeq and MiSeq) you have that primer synthesized and HPLC purified.
Use the primer at 100uM.
Whoever is doing you sequencing will know how to use it. -
If you are sequencing a small number of plasmid-derived inserts, then you are likely to not need the full number of reads in a lane. An alternative to creating a custom primer is to just spike your library into a control lane of PhiX on a HiSeq, or mix in a higher-complexity library (usually someone has something they want a little more sequence for) on a MiSeq. It seems like the recent software changes have made the MiSeq less sensitive to complexity reductions anyway.Providing nextRAD genotyping and PacBio sequencing services. http://snpsaurus.comComment
-
Please can your help in any library for plasmodium gametocytes. Thnaks . ErnyComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment